文献速递青光眼

Aurolab 引流植入物颞上 versus 鼻下象限放置结局比较

Comparison of outcomes between Aurolab aqueous drainage implant placed in the superotemporal versus inferonasal quadrant.
PubMed 文献 · Br J Ophthalmol · 2020-06-17

该回顾性研究比较成人难治性青光眼行 Aurolab 水引流植入物(AADI)颞上象限与鼻下象限放置的结局,共纳入鼻下组 84 眼、颞上组 69 眼,随访至少 2 年。两组眼压下降、视力、降眼压药物数量及并发症相似,2 年无降眼压药物累计成功率鼻下组 57.1%、颞上组 50.7%(p=0.47)。结论认为鼻下放置与颞上放置同样安全有效。

要点

  • 鼻下与颞上象限放置 AADI 在 2 年随访中眼压、视力及并发症相似。
  • 2 年无降眼压药物累计成功率鼻下组 57.1%、颞上组 50.7%(p=0.47)。
  • 鼻下放置可作为特定临床情况下的同等安全有效选择。

核心结论

  • 鼻下象限放置 AADI 与颞上象限放置相比,在成人难治性青光眼中同样安全有效。

研究设计与样本

  • 回顾性研究,纳入完成至少 2 年随访的 AADI 放置眼,鼻下象限 84 眼、颞上象限 69 眼。
  • 象限选择由术者根据瘢痕量和结膜活动度决定。

主要发现

  • 两组在 3 个月随访时眼压均显著下降(鼻下组 18.4±10.4 mm Hg,颞上组 17.7±11.1 mm Hg;p=0.63),并维持至末次随访。
  • 两组在各时间点的最佳矫正视力、眼压、降眼压药物数量及并发症相似。
  • 2 年无降眼压药物累计成功率鼻下组 57.1%(47.1%-68.1%),颞上组 50.7%(39.8%-63.1%)(p=0.47)。

关键数值与推荐

  • 累计失败定义为:3 个月后连续两次随访眼压 >21 mm Hg 或未较基线下降 20%,或连续两次随访眼压 ≤5 mm Hg,或因青光眼或并发症再手术,或丧失光感视力。

临床怎么用

  • 在结膜瘢痕或活动度受限等特定临床情况下,可选择鼻下象限放置 AADI。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To determine the outcomes of Aurolab aqueous drainage implant (AADI) placed in the superotemporal versus the inferonasal quadrant in adult eyes with refractory glaucoma. METHODS: This was a retrospective study of eyes that had AADI placement and completed a minimum of 2-year follow-up. The choice of the quadrant was at the surgeon's discretion and mainly depended on the amount of scarring and conjunctival mobility. The cumulative failure rate of the AADI was defined as intraocular pressure (IOP) >21 mm Hg or not reduced by 20% below baseline on two consecutive follow-up visits after 3 months, IOP ≤5 mm Hg on two consecutive follow-up visits after 3 months, reoperation for glaucoma or a complication, or loss of light perception vision. RESULTS: We included 84 eyes with AADI in the inferonasal quadrant versus 69 eyes in the superotemporal quadrant. A significant drop in IOP was seen in both groups (18.4±10.4 mm Hg in the inferonasal group vs 17.7±11.1 mm Hg in the superotemporal group; p=0.63) at 3-month follow-up and this was maintained until last follow-up. Best-corrected visual acuity, IOP, number of IOP-lowering medications and complications were similar between the two groups at all time points. The cumulative success rate at 2-year follow-up without IOP-lowering medications was 57.1% (47.1%-68.1%) in the inferonasal group and 50.7% (39.8%-63.1%) in the superotemporal group (p=0.47). CONCLUSIONS: Inferonasal AADI placement appears to be an equally safe and effective surgical option compared with superotemporal AADI placement and may be helpful in certain clinical situations.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Puthuran GV, Palmberg PF, Wijesinghe HK, et al. Comparison of outcomes between Aurolab aqueous drainage implant placed in the superotemporal versus inferonasal quadrant. Br J Ophthalmol. 2020. PMID: 32554442. doi:10.1136/bjophthalmol-2019-315558

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。